News

Moderna says updated Covid-19 vaccine booster shows stronger antibody response against Omicron

Published

on

Bivalent boosters handle two viral strains in the identical vaccine. The up to date booster incorporates Moderna’s authentic vaccine, and a vaccine candidate that targets the Omicron variant.

The vaccine was usually well-tolerated, the corporate mentioned, with unwanted side effects much like booster doses of the present vaccine.

The 50-microgram bivalent booster, known as mRNA-1273.214, generated a stronger antibody response in opposition to Omicron than the unique Moderna vaccine. Omicron subvariants are driving nearly all the brand new Covid-19 instances in the US proper now.

Stéphane Bancel, chief government officer of Moderna, mentioned in a information launch “we anticipate extra sturdy safety in opposition to variants of concern with mRNA-1273.214, making it our lead candidate for a Fall 2022 booster.”
He mentioned the corporate will submit its preliminary knowledge and evaluation to regulators in order that the Omicron-containing bivalent booster will probably be out there in late summer season. The US Meals and Drug Administration’s vaccine advisers are set to satisfy June 28 to debate whether or not coronavirus vaccine compositions ought to be modified for fall 2022.

In April, Moderna introduced its first bivalent Covid-19 booster shot candidate — which mixed components of the present vaccine with updates primarily based on the Beta variant — induced larger antibody responses in opposition to all variants of concern, together with Omicron, when in comparison with the corporate’s authentic Covid-19 booster shot.

Advertisement

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Trending

Exit mobile version